Pharma News

Eugia Pharma  receives a warning letter from FDA which summarizes significant violations of Current Good Manufacturing Practice (CGMP) regulations for finished pharmaceuticals.

U.S. Food and Drug Administration (FDA) inspected a drug manufacturing facility of Eugia Pharma Specialities Limited (Unit III), at Patancheru (Mandal), Sangareddy, Hyderabad, Telangana, from January 22 to February 2, 2024. It is a wholly owned subsidiary of the Aurobindo Pharma.

Indoco Remedies receives final ANDA approval from the USFDA  for Lofexidine Tablets 0.18 mg with Competitive Generic Therapy designation, It is a generic equivalent of Lucemyra Tablets, 0.18 mg of USWM, LLC.

Union Minister of Health and Family Welfare & Chemicals and Fertilizers, Shri J.P. Nadda inaugurated the ‘First Policy Makers’ Forum’, here today, which will run until 22nd August 2024. To elevate India's position in the global pharmaceutical sector, the Indian Pharmacopoeia Commission (IPC), in collaboration with the Ministry of Health & Family Welfare and the Ministry of External Affairs, hosted an international delegation of policymakers and drug regulators from 15 countries.

A unique influenza vaccine candidate that’s inhaled and based on technology developed by University of Wisconsin–Madison researchers is safe and could bolster protection against seasonal and pandemic influenza for people vulnerable to severe disease when they receive it in addition to the annual flu shot.

Alembic Pharmaceuticals Limited, a vertically integrated research and development pharmaceutical company, has been at the forefront of healthcare since 1907. Headquartered in India, Alembic is a publicly listed company that manufactures and markets generic pharmaceutical products all over the world. Alembic's state of the art research and manufacturing facilities are approved by regulatory authorities of many developed countries including the USFDA. Alembic is one of the leaders in branded generics in India.